Primary hemostasis

Journal of Veterinary Emergency and Critical Care

Volumn 15, Issue 1, 2005, Pages 1-8

  McMichael, Maureen ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Aggregation; Aspirin; Coagulation; Platelet; Thromboxane; Von willebrand factor

Indexed keywords

ANIMALIA;

EID: 27744441510     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2005.04021.x     Document Type: Review

References (77)

1. Ruiz-Gopegui R. Congenital and acquired vascular wall diseases, In: Feldman BF, Zinkl JG, Jain NC. eds. Schalm's Veterinary Hematology. Philadelphia: Lippincott, Williams, & Wilkins; 2000, pp. 528-531.
2. Good L, Manning A. Thromboembolic disease: predispostion and clinical management. Comp Cont Educ Pract Vet 2003; 25:660-674.
3. Thomas S. Platelet membrane glycoproteins in haemostasis. Clin Lab 2002; 48:247-262.
4. Heilman E, Friese P, Anderson S, et al. Biotinylated platelets: a new approach to the measurement of platelet lifespan. Br J Haematol 1993; 85:729-735.
5. Vincent JL, Yagushi A, Pradier O. Platelet function in sepsis. Crit Care Med 2002; 30:S313-S317.
6. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002; 22:913-922.
7. Meseguer J, Esteban MA, Rodriguez A. Are thrombocytes and platelets true phagocytes? Microsc Res Tech 2002; 57:491-497.
8. Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003; 1:1335-1342.
9. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2003; 1:1602-1612.
10. Meyer D, Pietu G, Fressinaud E, et al. von Willebrand factor: structure and function. Mayo Clin Proc 1991; 66:516-523.
11. Shattil SJ. Signaling through platelet integrin alpha IIb beta 3: inside-out, outside-in, and sideways. Thromb Haemost 1999; 82:318-325.
12. Turitto V, Muggli R, Baumgartner HR. Physical factors influencing platelet deposition on subendothelium: importance of blood shear rate. Ann NY Acad Sci 1977; 283:284-290.
13. Caen JP, Michel H, Tobelem G. Adhesion and aggregation of human platelet to rabbit subendothelium: a new approach for investigation; specific antibodies. Experientia 1976; 33:91-103.
14. Nurden AT, Caen JP. Specific roles for platelet surface glycoproteins in platelet function. Nature 1975; 255:720-722.
15. Frenette PS, Johnson RC, Hynes RO, et al. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA 1995; 92:7450-7454.
16. Agbanyo FR, Sixma JJ, de Groot PG, et al. Thrombospondin-platelet interactions. Role of divalent cations, wall shear rate, and platelet membrane glycoproteins. J Clin Invest 1993; 92:288-296.
17. 2+ ions, shear rate, and platelet membrane glycoproteins. Blood 1992; 79:928-935.
18. Nievelstein PF, D' Alessio PA, Sixma JJ. Fibronectin in platelet adhesion to human collagen types I and III. Use of nonfibrillar and fibrillar collagen in flowing blood studies. Arteriosclerosis 1988; 8:200-206.
19. Beumer S, Ijsseldijk MJ, de Groot PG, et al. Platelet adhesion to fibronectin in flow: dependence on surface concentration and shear rate, role of platelet membrane glycoproteins GP IIb/IIIa and VLA-5, and inhibition by heparin. Blood 1994; 84:3724-3733.
20. Kroll MH, Hellums JD, McIntire LV, et al. Platelets and shear stress. Blood 1996; 88:1525-1541.
21. Beumer S, Heijnen HF, Ijsseldijk MJ, et al. Platelet adhesion to fibronectin in flow: the importance of von Willebrand factor and glycoprotein Ib. Blood 1995; 86:3452-3460.
22. Abrams C, Brass LF. Platelet signal transduction, In: Colman R, Hirsh J, Marder VJ, Clowes AW, George JN. eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia: Lippincott, Williams & Wilkins; 2001, pp. 541-560.
23. Detwiler TC, Charo IF, Feinman RD. Evidence that calcium regulates platelet function. Thromb Haemost 1978; 40:207-211.
24. LeBreton G, Dinerstein R, Roth L. Direct evidence for intracellular divalent cation redistribution associated with platelet shape change. Biochem Biophys Res Commun 1976; 71:362-369.
25. Hawiger J, Steer M, Salzman EW. Intracellular regulatory processes in platelet, In: Colman R, Hirsh J, Marder VJ, Clowes AW, George JN. eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: JB Lippincott Co.; 1987, pp. 710-725.
26. Funk C. Platelet Eicosanoids, In: Colman R, Hirsh J, Marder VJ, Clowes AW, George JN. eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott, Williams, & Wilkins; 2001, pp. 533-540.
27. Moake JL, Turner NA, Stathopoulos NA, et al. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988; 71:1366-1374.
28. Hardwick RA, Hellums JD, Peterson DM, et al. The effect of PGI2 and theophylline on the response of platelets subjected to shear stress. Blood 1981; 58:678-681.
29. Konstantopoulos K, Wu KK, Udden MM, et al. Flow cytometric studies of platelet responses to shear stress in whole blood. Biorheology 1995; 32:73-93.
30. Ashby B, Colman R, Daniel J, et al. Platelet stimulatory and inhibitory receptors, In: Colman R, Hirsh J, Marder VJ, Clowes AW, George JN. eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia: Lippincott, Williams & Wilkins; 2001, pp. 505-520.
31. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 2001; 88:756-762.
32. Rosenzweig A. Endothelial progenitor cells. N Engl J Med 2003; 348:581-582.
33. Selak MA, Chignard M, Smith JB. Cathepsin G is a strong platelet agonist released by neutrophils. Biochem J 1988; 251:293-299.
34. Cassar K, Bachoo P, Brittenden J. The role of platelets in peripheral vascular disease. Eur J Vasc Endovasc Surg 2003; 25:6-15.
35. Prater MR. Focus on platelet problems: too few, too many, and too defunct, In: Davenport DJ. ed. Proceedings of the 21st Symposium of the American College of Veterinary Internal Medicine. North Carolina, 4-5 June 2003. 2003; pp. 706-708.
36. Ruiz de gopegiu R, Feldman BF. Acquired and inherited platelet dysfunction in small animals. Comp Cont Ed Pract Vet 1998; 20:1039-1052.
37. Boudreaux MK. Progress in the biological and molecular characterization of coagulation and platelet disorders in dogs, In: Davenport DJ, Lester GD, Green R. eds. Proceedings of the 20th Annual ACVIM Forum. Lakewood: 2002, pp. 624-629.
38. Ates E, Bakkaloglu A, Saatci U, et al. von Willebrand factor antigen compared with other factors in vasculitic syndromes. Arch Dis Child 1994; 70:40-43.
39. Stevens TR, James JP, Simmonds NJ, et al. Circulating von Willebrand factor in inflammatory bowel disease. Gut 1992; 33:502-506.
40. Blann AD. von Willebrand factor antigen as an acute phase reactant and marker of endothelial cell injury in connective tissue diseases: a comparison with CRP, rheumatoid factor, and erythrocyte sedimentation rate. Z Rheumatol 1991; 50:320-322.
41. Pottinger BE, Read RC, Paleolog EM, et al. von Willebrand factor is an acute phase reactant in man. Thromb Res 1989; 53:387-394.
42. George JN, Vesely SK, Rizvi MA. Thrombotic thrombocytopenic purpura- hemolytic-uremic syndrome, In: Colman R, Hirsh J, Marder VJ, Clowes AW, George JN. eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia: Lippincott, Williams, & Wilkins; 2001, pp. 1235-1242.
43. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
44. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
45. Boyce TG, Swerdlow DL, Griffin PM. Escherichia coli O157: H7 and the hemolytic-uremic syndrome. N Engl J Med 1995; 333:364-368.
46. Chantrey J, Chapman PS, Patterson-Kan JC. Haemolytic-uraemic syndrome in a dog. J Vet Med A Physiol Pathol Clin Med 2002; 49:470-472.
47. Moake JL. Studies on the pathophysiology of thrombotic thrombocytopenic purpura. Semin Hematol 1997; 34:83-89.
48. Moake JL, Chow TW. Increased von Willebrand factor (vWf) binding to platelets associated with impaired vWf breakdown in thrombotic thrombocytopenic purpura. J Clin Apheresis 1998; 13:126-132.
49. Paquette RL, Tran L, Landaw EM. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis. Bone Marrow Transplant 1998; 22:351-357.
50. Mannucci PM, Ruggeri ZM, Pareti FI, et al. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977; 1:869-872.
51. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90:2515-2521.
52. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992; 82:87-93.
53. Ruiz de gopegiu R, Feldman BF. Platelets and von Willebrand's disease, In: Ettinger S, Felman EC. eds. Textbook of Veterinary Internal Medicine. Philadelphia: WB Saunders Co; 2000, pp. 1817-1827.
54. Deitcher SR, Carman TL. Heparin-induced thrombocytopenia: natural history, diagnosis, and management. Vasc Med 2001; 6: 113-119.
55. Feldman BF. Primary hemostasis: the vessel wall and platelets, In: Davenport DJ. ed. Proceedings of the 21st Symposium of the American College of Veterinary Internal Medicine. North Carolina, 4-5 June 2003. 2003; pp. 699-700.
56. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003; 2:15-28.
57. Clarke RJ, Mayo G, Price P, et al. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325:1137-1141.
58. Behrend EN, Grauer GF, Greco DS, et al. Comparison of the effects of diltiazem and aspirin on platelet aggregation in cats. J Am Anim Hosp Assoc 1996; 32:11-18.
59. Allen DG, Johnstone IB, Crane S. Effects of aspirin and propranolol alone and in combination on hemostatic determinants in the healthy cat. Am J Vet Res 1985; 46:660-663.
60. Smith SA, Tobias AH, Jacob KA, et al. Arterial thromboembolism in cats: acute crisis in 127 cases (1992-2001) and long-term management with low-dose aspirin in 24 cases. J Vet Intern Med 2003; 17:73-83.
61. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel versus Aspirin Patency Trial (RAPT). Circulation 1994; 89:588-595.
62. Langleben D, Christman BW, Barst RJ, et al. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J 2002; 143:E4.
63. Wallace JL, Soldato PD. The therapeutic potential of NO-NSAIDs. Fund Clin Pharmacol 2003; 17:11-20.
64. Wallace JL, McKnight W, Del Soldato P, et al. Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest 1995; 96:2711-2718.
65. Yamamoto T, Kakar NR, Vina ER, et al. The effect of aspirin and two nitric oxide donors on the infarcted heart in situ. Life Sci 2000; 67:839-846.
66. Fiorucci S, Santucci L, Mencarelli A, et al. Gastrointestinal safety of a NO-releasing aspirin derivative (NCX4016) in humans: a double blind placebo controlled endoscopic study. Gastroenterology 2002; 122:A54.
67. Hawkey C, Jones J, Atherton C, et al. Gastrointestinal safety of AZD3582: a new chemical entity with a novel multipathway mechanism of action. Gastroenterology 2002; 122:A54.
68. Bhatt DL;, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. J Am Med Assoc 2000; 284:1549-1558.
69. Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002; 113:1-6.
70. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344:1888-1894.
71. O'Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein IIb/ IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. J Am Med Assoc 2001; 285:2468-2473.
72. Chew DP, Bhatt DL. Oral glycoprotein IIb/IIIa antagonists in coronary artery disease. Curr Cardiol Rep 2001; 3:63-71.
73. Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103: 201-206.
74. Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. J Am Med Assoc 1999; 281:806-810.
75. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-1339.
76. Moshfegh K, Redondo M, Julmy F, et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol 2000; 36:699-705.
77. Rupprecht HJ, Darius H, Borkowski U, et al. Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 1998; 97:1046-1052.